

S1 Table. Remission induction and consolidation

Drug	Dose	Days
Prephase (1 wk)		
Prednisolone (PO) ^{a)}	60 mg/m ² (max. 80 mg)	1-7
Methotrexate/Cytarabine/ Hydrocortisone (IT)	By age ^{b)}	1
Remission induction (4 wk)		
Vincristine (IV)	1.5 mg/m ² (max. 2 mg)	1, 8, 15, 22
Daunorubicin (IV)	45 mg/m ²	1
l-asparaginase (IM)	6,000 u/m ² (max, 10,000 u)	2, 4, 6, 9, 11, 13, 16, 18, 20
Prednisolone (PO)	60 mg/m ² (max. 80 mg)	1-21
Methotrexate (IT)	By age ^{c)}	1, 22
Consolidation (8 wk)		
Cyclophosphamide (IV)	1,000 mg/m ²	1, 29
Cytarabine (IV)	100 mg/m ²	1-5, 15-19, 29-33, 43-47
Vincristine (IV)	1.5 mg/m ² (max. 2 mg)	15, 22, 43, 50
Prednisolone (PO)	45 mg/m ² (max. 60 mg)	22-26, 50-54
6-Mercaptopurine (PO)	60 mg/m ²	1-7, 29-35
Methotrexate (IT)	By age ^{c)}	1, 15, 29, 43

IT, intrathecal; IV, intravenous; PO, per os. ^{a)}For patients diagnosed and treated from January 2009 onwards, prednisolone was used for treatment. However, for patients diagnosed from January 2005 to December 2008, dexamethasone was used at a dose of 8 mg/m²/day PO (max. 10 mg/day) during all phases of steroid treatment from prephase to end of maintenance treatment, ^{b)}Age-adjusted doses of triple intrathecal chemotherapy: Methotrexate 6 mg (<1 year), 7.5 mg (≥ 1 and < 2 years), 10 mg (≥ 2 and < 3 years), 12.5 mg (≥ 3 years); cytarabine 12 mg (<1 year), 15 mg (≥ 1 and < 2 years), 20 mg (≥ 2 and < 3 years), 25 mg (≥ 3 years); hydrocortisone 12 mg (<1 year), 15 mg (≥ 1 and < 2 years), 20 mg (≥ 2 and < 3 years), 25 mg (≥ 3 years), ^{c)}Age-adjusted doses of intrathecal methotrexate: 6 mg (<1 year), 7.5 mg (≥ 1 and < 2 years), 10 mg (≥ 2 and < 3 years), 12.5 mg (≥ 3 years).